Biohaven Ltd.

Biohaven Ltd. (BHVN, New Haven CT, incorporated in British Virgin Islands), a clinical-stage pharmaceutical company focused on neurological and psychiatric disorders, filed a current report on August 26, 2026 disclosing entry into a material definitive agreement (Item 1.01) alongside a Reg FD disclosure (Item 7.01) and exhibits (Item 9.01). A new material agreement for a clinical-stage pharma company typically signals a licensing deal, research collaboration, manufacturing partnership, or financing arrangement. The specific agreement terms, counterparty, and financial consideration are in attached exhibits. The combination with a Reg FD disclosure suggests this was a publicly announced transaction.

John Yetimoglu filed Form 3 as a newly appointed director of Biohaven Ltd., with an event date of August 6, 2026. He beneficially owns 6,250,000 common shares of Biohaven indirectly through Infinitum Cayman Master, Ltd., where he serves as Chief Investment Officer. The 6.25 million share position held by Infinitum represents a significant institutional ownership stake in Biohaven, making this a notable initial director disclosure beyond routine Form 3 filings.

Biohaven Ltd. appointed John Yetimoglu as a director effective August 6, 2026, with his term expiring at the 2027 Annual Meeting of Shareholders. He was simultaneously named to the Nominating and Governance Committee. Per the non-employee director compensation policy, Yetimoglu received options with a grant date fair value of $713,875, vesting 25% at grant and 25% on each of the following three anniversaries, plus a $57,000 annual retainer. This is a routine board appointment with standard compensation terms.

Warren Karl Volles, Chief Legal Officer of Biohaven Ltd, filed a Form 3 initial ownership statement upon becoming a Section 16 reporting person, disclosing beneficial ownership of 248,212 direct shares plus stock options in BHVN. Standard initial Section 16(a) disclosure required within 10 days of becoming an insider.

Biohaven Ltd. announced that Chief Scientific Officer Bruce Car will transition from his full-time role to a part-time position as Chief Innovation Officer. Concurrently, Dr. David Pirman was promoted to Executive Vice President and Head of Discovery, taking on the operational scientific leadership previously held by Car. The transition is described as planned and collegial, not a departure. Pirman's promotion signals Biohaven's continued investment in its early-stage pipeline, with a focus on ion channel and synaptic biology programs.

Biohaven Ltd. (BHVN) filed an 8-K under Item 7.01 (Reg FD) to disclose investor conference or presentation materials. Regulation FD requires companies to disclose material non-public information broadly to all investors simultaneously rather than selectively. The presentation materials are typically attached as an exhibit, covering business updates, financial guidance, or strategic priorities. Investors should review these materials for any forward-looking statements or updates relative to prior guidance.

BHVN filed a 424B5 prospectus supplement dated 2026-05-04, representing an active capital markets transaction. Offering size: approximately $300.0 million. This represents immediate dilution to existing shareholders.

BHVN filed a S-3ASR (automatic shelf) shelf registration statement dated 2026-05-04. This is primarily a resale shelf for existing stockholders — not new share issuance — limiting direct dilution to public investors. No immediate capital raise is triggered; watch for prospectus supplements disclosing actual transactions.